1. Scrip
  2. >>Focus On Asia

Daewoong's SGLT-2 Inhibitor Set For First Filing After Phase III

First Korean Contender In Class

 
• By Jung Won Shin

Korean pharma firm poised to file for domestic approval of SGLT-2 inhibitor enavogliflozin after positive top-line Phase III data, marking progress for the country's first drug in the already crowded class. But will it be competitive?

diabetes
Daewoong Speeds Up Novel Drug Development • Source: Alamy

Daewoong Pharmaceutical Company Ltd. has unveiled promising top-line Phase III results for enavogliflozin both as monotherapy and in combination with metformin for the treatment of type 2 diabetes, potentially moving the first sodium-glucose co-transporter 2 (SGLT-2) inhibitor to be developed by a Korean company closer to launch.

If approved by South Korea’s Ministry of Food and Drug Safety after a planned filing soon, enavogliflozin will then have to compete with a number of other same-class drugs from multinationals already available in the country, While Daewoong sees it as potentially better than these rivals, it seems likely that demonstration of

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from South Korea

More from Focus On Asia

Multiple Launches Help Lilly’s Japan Growth

 
• By Ian Haydock

Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.

China Biopharma Podcast

 
• By Dexter Jie Yan and Xu Hu

Join our China-based editors Dexter Yan and Xu Hu in this Chinese-language podcast looking at some of their recent interviews and other key coverage.

Celltrion Sees Multiple Biosimilar Opportunities From Trump’s Pricing EO

 
• By Jung Won Shin

Biosimilars giant Celltrion tells shareholders there could be multiple opportunities for its business under US President Donald Trump’s latest executive order on drug pricing.